Dear Colleagues,

We are reaching out to all of you against the backdrop of the COVID-19 pandemic. Our network’s highest priority at present is the safety and well-being of both network staff and trial participants. We know sites are taking every precaution necessary to ensure the safety of staff and participants, as well as following any institutional requirements in this regard. We also know site staff have considered other measures, such as reminding participants to assess for COVID-19 exposure and symptoms, and to not report for study visits if they experience either.

The following are the HIV Prevention Trials Network (HPTN) recommendations regarding our current studies:

1. No new studies will be initiated until further notice.
2. Observational studies will be paused.
3. All screening and enrollments in ongoing studies will be paused until further notice.
4. Follow-up should continue for participants currently enrolled in studies with guidance from specific protocol team leadership.

For ongoing clinical trials that include interventions, the U.S. Division of AIDS (DAIDS) has provided the attached guidance to the Networks, protocol teams and clinical research sites. In addition, study teams are actively developing plans for study conduct and contingencies for routine study visits consistent with current COVID-19 guidance.

We will continue to monitor the situation and will share with you any relevant updates. In the interim, please do not hesitate to contact HPTN Leadership with any concerns.

Warm Regards,

Mike Cohen, MD                      Wafaa El-Sadr, MD, MPH, MPA

HPTN Principal Investigators